Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry

European Journal of Heart Failure

Volumn 19, Issue 10, 2017, Pages 1270-1279

  Lund, Lars H ^a,b   Braunschweig, Frieder ^a,b   Benson, Lina ^c   Ståhlberg, Marcus ^a,b   Dahlström, Ulf ^d   Linde, Cecilia ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cardiac resynchronization therapy; Epidemiology; Guidelines; Heart failure; Implementation; Utilization

Indexed keywords

CARDIOVASCULAR AGENT;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE REGISTRY; DRUG USE; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEART FAILURE; HUMAN; ICD-10; INCOME; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE PLANNING; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SOCIOECONOMICS; SWEDEN; THERAPY EFFECT; TREATMENT INDICATION; UNIVERSITY; MIDDLE AGED; REGISTER; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIAC RESYNCHRONIZATION THERAPY; DEMOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; SOCIOECONOMIC FACTORS; SWEDEN; TREATMENT OUTCOME;

EID: 85012037027     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.781     Document Type: Article

References (26)

1. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547–3556.
2. Raatikainen MJ, Arnar DO, Zeppenfeld K, Merino JL, Levya F, Hindriks G, Kuck KH. Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace 2015;17 Suppl 1:i1–i75.
3. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, Larson EL, Scheinberg D, Reece EA, Slavkin H, Dobs A, Grebb J, Martinez RA, Korn A, Rimoin D. Central challenges facing the national clinical research enterprise. JAMA 2003;289:1278–1287.
4. Lund LH, Jurga J, Edner M, Benson L, Dahlstrom U, Linde C, Alehagen U. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013;34:529–539.
5. Lund LH, Benson L, Stahlberg M, Braunschweig F, Edner M, Dahlstrom U, Linde C. Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14 713 patients in the Swedish Heart Failure Registry. Eur J Heart Fail 2014;16:1073–1081.
6. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U, Alehagen U, Lund LH. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace 2015;17:424–431.
7. Braunschweig F, Linde C, Benson L, Stahlberg M, Dahlstrom U, Lund LH. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy. Eur J Heart Fail 2017;19:in press.
8. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281–2329.
9. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
10. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012;308:2108–2117.
11. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
12. Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence-based therapy and survival in heart failure in Sweden 2003–2012. Eur J Heart Fail 2016;18:503–511.
13. Bogale N, Priori S, Cleland JG, Brugada J, Linde C, Auricchio A, van Veldhuisen DJ, Limbourg T, Gitt A, Gras D, Stellbrink C, Gasparini M, Metra M, Derumeaux G, Gadler F, Buga L, Dickstein K. The European CRT Survey: 1 year (9–15 months) follow-up results. Eur J Heart Fail 2012;14:61–73.
14. Loh JC, Creaser J, Rourke DA, Livingston N, Harrison TK, Vandenbogaart E, Moriguchi J, Hamilton MA, Tseng CH, Fonarow GC, Horwich TB. Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993–2010: findings from a university referral center. Circ Heart Fail 2013;6:411–419.
15. Bank AJ, Gage RM, Olshansky B. On the underutilization of cardiac resynchronization therapy. J Card Fail 2014;20:696–705.
16. Hubinette C, Lund LH, Gadler F, Stahlberg M. Awareness of indications for device therapy among a broad range of physicians: a survey study. Europace 2014;16:1580–1586.
17. Colvin M, Sweitzer NK, Albert NM, Krishnamani R, Rich MW, Stough WG, Walsh MN, Westlake Canary CA, Allen LA, Bonnell MR, Carson PE, Chan MC, Dickinson MG, Dries DL, Ewald GA, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Moore S, Rodgers JE, Rogers JG, Vest AR, Whellan DJ, Givertz MM. Heart failure in non-caucasians, women, and older adults: a White Paper on Special Populations from the Heart Failure Society of America Guideline Committee. J Card Fail 2015;21:674–693.
18. Heidenreich PA, Tsai V, Bao H, Curtis J, Goldstein M, Curtis L, Hernandez A, Peterson P, Turakhia MP, Masoudi FA. Does age influence cardiac resynchronization therapy use and outcome? JACC Heart Fail 2015;3:497–504.
19. Woods B, Hawkins N, Mealing S, Sutton A, Abraham WT, Beshai JF, Klein H, Sculpher M, Plummer CJ, Cowie MR. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015;101:1800–1806.
20. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O'Callaghan KM, Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014;174:1340–1348.
21. Zabarovskaja S, Gadler F, Braunschweig F, Stahlberg M, Hornsten J, Linde C, Lund LH. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace 2012;14:1148–1155.
22. Stromberg A, Martensson J. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs 2003;2:7–18.
23. Miller RJ, Howlett JG, Exner DV, Campbell PM, Grant AD, Wilton SB. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis. Can J Cardiol 2015;31:792–799.
24. Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiade M, Heywood JT, Liu Y, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. Pacing Clin Electrophysiol 2013;36:433–443.
25. Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, Gitt A, Limbourg T, Linde C, Dickstein K. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail 2011;13:974–983.
26. Dickstein K, Normand C, Anker SD, Auricchio A, Blomstrom CL, Bogale N, Cleland J, Filippatos G, Gasparini M, Gitt A, Hindricks G, Kuck KH, Ponikowski P, Stellbrink C, Ruschitzka F, Linde C. European cardiac resynchronization therapy survey II: rationale and design. Europace 2015;17:137–141.